Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

Seven abstracts represent data across migraine, childhood-onset epilepsy and multiple system atrophy (MSA), highlighting Lundbeck's biology-driven approach to developing treatments for serious brain diseases

Apr. 13, 2026 at 7:40am

Got story updates? Submit your updates here. ›

An abstract illustration of a brain-related medical object, such as a neuron or synaptic connection, defined by bright neon lines against a dark background, conveying the innovative and energetic nature of Lundbeck's neuroscience research.Lundbeck's neuroscience research illuminates new possibilities for treating complex brain disorders.Chicago Today

Lundbeck announced that new data across its neurology portfolio will be presented at the American Academy of Neurology (AAN) Annual Meeting 2026, including Phase 1 safety and tolerability data for bocunebart, an investigational anti-PACAP monoclonal antibody in migraine prevention, as well as updates on its VYEPTI (eptinezumab) migraine treatment and bexicaserin for developmental and epileptic encephalopathies (DEEs). The presentations underscore Lundbeck's focus on advancing brain disease treatments where there is significant unmet need.

Why it matters

Neuroscience is reaching an inflection point, with progress in human genetics, biomarker validation, and the understanding of neuro-rare and migraine disease biology opening new possibilities. Lundbeck's approach is to translate these insights into drug development programs that validate mechanisms early and focus on areas where patients still have few or no treatment options.

The details

Among the highlights are new Phase 1 data on bocunebart, a potential first-in-class investigational monoclonal antibody that targets pituitary adenylate cyclase-activating polypeptide (PACAP), a pathway distinct from the calcitonin gene-related peptide (CGRP) mechanism targeted by current preventive migraine therapies. Lundbeck will also present data on eptinezumab, an intravenous anti-CGRP preventive treatment for migraine, including a post-hoc analysis from the DELIVER trial and interim findings from the ongoing INFUSE real-world study. In rare childhood-onset epilepsy, Lundbeck will present primary 12-month results from the open-label extension of the Phase 1b/2a PACIFIC trial evaluating bexicaserin. Separately, findings will be presented from a Delphi consensus study in multiple system atrophy (MSA), a rare neurodegenerative movement disorder.

  • The American Academy of Neurology (AAN) Annual Meeting 2026 will take place April 18–22 in Chicago, U.S.

The players

Lundbeck

A biopharmaceutical company focusing exclusively on brain health, with more than 70 years of experience in neuroscience and a commitment to improving the lives of people with neurological and psychiatric diseases.

Johan Luthman

EVP and Head of Research & Development at Lundbeck.

bocunebart

An investigational monoclonal antibody (mAb) that binds to and inhibits the signaling of pituitary adenylate cyclase-activating polypeptide (PACAP), a neuropeptide implicated in migraine pathophysiology.

VYEPTI® (eptinezumab)

A humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and was developed for intravenous administration as a preventive treatment for migraine.

bexicaserin

An investigational, oral, centrally acting, highly selective superagonist of the 5-HT2C receptor, being evaluated for the treatment of seizures in participants with any type of developmental and epileptic encephalopathy (DEE).

Got photos? Submit your photos here. ›

What they’re saying

“Neuroscience is reaching an inflection point. Progress in human genetics, biomarker validation, and the understanding of neuro-rare and migraine disease biology is opening new possibilities. Our approach is to translate these insights into drug development programs that validate mechanisms early and focus on areas where patients still have few or no treatment options.”

— Johan Luthman, EVP and Head of Research & Development at Lundbeck

The takeaway

Lundbeck's presentations at the AAN Annual Meeting showcase its expanding neurology pipeline and continued commitment to advancing treatments for serious brain diseases, including migraine, developmental and epileptic encephalopathies, and multiple system atrophy, where there remains significant unmet medical need.